神經退化性疾病的全球市場:各適應症，各類藥物，各流通管道，各地區，機會，預測，2018年～2032年

全球神經退化性疾病市場規模預計將從2024年的552.1億美元增長至2032年的985.4億美元，在2025-2032年的預測期內，複合年增長率為7.51%。由於人口增長、研發投入以及治療藥物的技術創新，全球神經退化性疾病正在經歷快速增長。

由於全球人口老化以及阿茲海默症和帕金森氏症的高發生率，神經退化性疾病市場正在經歷顯著增長。這種成長也得益於對新型生物標記和診斷方法開發的投資不斷增加，這些方法不僅可以控制疾病症狀，還可以介入疾病本身。此外，利用新型基因技術和生物標記實現精準醫療、從症狀治療轉向疾病修飾治療，以及瞄準神經退化性疾病早期階段的治療，也是該領域的強勁趨勢。儘管這些疾病的發現和臨床開發面臨著複雜性（以及藥物開發成本）的課題，但在技術和創新、政府和私人部門對醫學研究的持續投資以及發現存在大量未滿足醫療需求的新市場方面，仍存在著巨大的機會。

此外，為了支持神經退化性疾病市場，賽諾菲公司於2025年5月宣布已收購Vigil Neuroscience, Inc.，這是一家臨床階段的生物技術公司，致力於為神經退化性疾病患者開發新型療法。此舉也增強了賽諾菲的早期研發管線，並使口服小分子TREM2激動劑VG-3927能夠進入阿茲海默症的2期臨床試驗。

本報告提供全球神經退化性疾病市場相關調查，提供市場概要，以及各適應症，各類藥物，各流通管道，各地區趨勢，及加入此市場的主要企業簡介等資訊。

目錄

第1章 計劃的範圍和定義

第2章 調查手法

第3章 美國的關稅的影響

第4章 摘要整理

第5章 全球神經退化性疾病市場預測，2018年～2032年

• 市場規模分析與預測
• 市場佔有率分析與預測
  • 各適應症
    • 阿茲海默症
    • 帕金森氏症
    • 肌肉萎縮性脊髓側索硬化症
    • 亨丁頓舞蹈症
    • 其他
  • 各類藥物
    • N-甲基-D-天冬氨酸(NMDA)受體拮抗劑
    • 膽鹼酯[酉每]抑制劑
    • 多巴胺促效劑
    • 免疫調節藥
    • 其他
  • 各流通管道
    • 醫院藥局
    • 零售藥局
    • 線上藥局
    • 其他
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 南美
    • 中東·非洲
  • 各企業市場佔有率分析(前五名公司以及其他- 各金額，2024年)
• 2024年的市場地圖分析

第6章 北美的神經退化性疾病市場預測，2018年～2032年

• 市場規模分析與預測
• 市場佔有率分析與預測
• 各國市場評估
  • 美國
  • 加拿大
  • 墨西哥

第7章 歐洲的神經退化性疾病市場預測，2018年～2032年

• 德國
• 法國
• 義大利
• 英國
• 俄羅斯
• 荷蘭
• 西班牙
• 土耳其
• 波蘭

第8章 亞太地區的神經退化性疾病市場預測，2018年～2032年

• 印度
• 中國
• 日本
• 澳洲
• 越南
• 韓國
• 印尼
• 菲律賓

第9章 南美的神經退化性疾病市場預測，2018年～2032年

• 巴西
• 阿根廷

第10章 中東·非洲的神經退化性疾病市場預測，2018年～2032年

• 沙烏地阿拉伯
• 阿拉伯聯合大公國
• 南非

第11章 需求供給分析

第12章 價值鏈分析

第13章 供應鏈分析

第14章 波特的五力分析

第15章 大環境分析

第16章 價格分析

第17章 市場動態

• 市場促進因素
• 市場課題

第18章 市場趨勢與發展

第19章 法規結構和革新

• 臨床試驗
• 法規當局的認證

第20章 專利的形勢

第21章 案例研究

第22章 競爭情形

• 前五名市場領導的競爭矩陣
• 前五名參與企業的SWOT分析
• 前10名市場主要企業的形勢
  • AbbVie Inc.
  • Novartis AG
  • Merck & Co., Inc
  • Biogen, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Pfizer Inc.
  • Sanofi S.A
  • GlaxoSmithKline PLC
  • UCB S.A.
  • H. Lundbeck A/S
  • Boehringer Ingelheim International GmbH

第23章 策略性建議

第24章 關於調查公司·免責聲明

Global neurodegenerative disease market is projected to witness a CAGR of 7.51% during the forecast period 2025-2032, growing from USD 55.21 billion in 2024 to USD 98.54 billion in 2032. The global neurodegenerative disease is experiencing rapid growth due to a growing population, investment in research and development, and innovation in therapeutic drugs.

The neurodegenerative disease market is undergoing significant growth, due to the increasing aging global population, leading to many instances of Alzheimer's and Parkinson's disease. The growth is also due to the increasing investment in developing new biomarkers or diagnostics to not only manage the symptoms of the disease but also to intervene on the disease itself. Additional strong trends in space are the move towards precision medicine with new genetic technologies or biomarkers, and the change from symptomatic therapies to disease-modifying therapies and targeting earlier stages of neurodegenerative disease. Despite the challenges of complexity (and drug development costs) in discovery and clinical development of these diseases, there are significant opportunities in technology and innovation, continuing government and private investments in medical research, and identifying new markets that have significant unmet medical needs.

Additionally, to support the neurodegenerative disease market in May 2025, Sanofi S.A. announced that enter into a transaction for Vigil Neuroscience, Inc., a clinical-stage biotechnology company that is publicly traded and develops novel therapies for people with neurodegenerative diseases. It also strengthens Sanofi's early-stage pipeline and provides entry into a phase 2 clinical study of VG-3927, an oral small-molecule TREM2 agonist, in Alzheimer's disease.

Increase in Population and Growing Awareness Support Market Expansion

The growing aging population and rising awareness concerning diseases are major drivers of the global market. As life expectancy increases, the risk of age-related diseases such as Alzheimer's and Parkinson's will ramp up demand for standard of care diagnostic tools, treatments, and long-term care post-diagnosis for an exponentially larger pool of patients. Significant research and development investments will emerge due to the combined effects of rising healthcare demand and the system's current overcapacity. The medical research funding will prioritize innovative disease-modifying treatments alongside advanced AI and digital health technologies. The increased public knowledge and efforts to detect neurodegenerative disorders sooner will generate greater market interest. A new generation of treatment models will develop which will deliver a better quality of life to vast populations dealing with these disorders. The new advancements will work toward creating medical solutions that can either reduce the rate of disease progression or completely stop its progression.

Additionally, to support aging populations who are affected by neurodegenerative disease, in March 2023, the Government of Canada announced it to invest USD 38.3 million in a research study to address the challenges of aging and brain health issues, including dementia, and provide quality of life for the aging population of Canada.

Rise in Investment in R&D Activities Boosts Market Demand

The market witnesses a rise in consumer demand as companies invest in research and development for the creation of new products. Organizations use research and development to detect unaddressed customer requirements and sometimes foresee upcoming market needs. Proper foresight plays an essential role because successful R&D work generates innovative solutions that customers enthusiastically adopt. Several types of innovation, including feature additions, performance enhancements, efficiency improvements, and brand-new functions, drive global market growth. The development of new product features enables companies to compete for customer choice. Companies conduct research and development work to enhance production processes, which helps them minimize manufacturing expenses. The cost savings resulting from better production processes permit companies to decrease their pricing to reach new customer groups. In addition, federations globally are announcing funds to address the rising demand and advancement in drug development.

For instance, in September 2023, the FDA announced that it has awarded over USD 16.9 million in funding over a next four-year period for important research through its Rare Neurodegenerative Disease Grant Program, including studies for amyotrophic lateral disease (ALS), and other rare neurodegenerative diseases, such as Niemann-Pick type C and myotonic dystrophy type 1.

Alzheimer's Diseases Holds Largest Global Neurodegenerative Disease Market Share

Alzheimer's Disease (AD) has the largest market share in neurodegenerative diseases, based primarily on the extent of its burden, with dementia being the most prevalent and common form, and the rapid growth of the aged population across the world. New disease-modifying therapies have brought about revolutionary market expansion through their ability to attack the root causes of diseases instead of basic symptoms. The growing burden of disease receives continuous research and development support, which drives advancements in drug development and diagnostic technology. The persistent dedication to research and development efforts keeps Alzheimer's disease at the forefront of medical institutions' focus for therapeutic and diagnostic solutions.

For instance, in December 2023, according to the Alzheimer's Association's report, about 6.7 million individuals aged 65 and older in the U.S. have Alzheimer's disease and estimates project to rise to 13.8 million by 2060.

North America Dominates Neurodegenerative Disease Market

North America has the dominant share of the neurodegenerative disease market due to its high prevalence, a well-established health care system, and an R&D commitment. Drug development leaders are in the United States, with Biogen (Alzheimer's), AbbVie (Parkinson's), and Ionis Pharmaceuticals (ALS) leading the innovation front. Other aspects of the region that promote growth are the upside in easy-to-access reimbursement from publicly funded insurance (Medicare) and private insurers, and an increasing aging population. North America also conducts significantly more clinical trials for screening and drugs for neurodegenerative disease therapies than other regions, which reduces the time to approval.

Additionally, to support health care infrastructure and clinical trial in March 2024

United State Congress approved a USD 100 million funding for National Institute of Health (NIH) to support Alzheimer's and dementia research for fiscal year 2024, and USD 34 million to support the BOLD Infrastructure Act an aspirational, bipartisan priority championed by the Alzheimer's Association and Alzheimer's Impact Movement (AIM). To receive such investment, scientists need to drive innovation and quality of treatment to prevent Alzheimer's.

Impact of U.S. Tariffs on the Global Neurodegenerative Disease Market

The U.S. tariffs will create substantial effects on the market for neurodegenerative diseases because they will boost expenses and disrupt pharmaceutical and medical equipment distribution networks. Cough suppressants and Alzheimer's and Parkinson's, and ALS medications depend on active pharmaceutical ingredients that enter the country through imports. Tariffs imposed on these items would result in higher production expenses, which would indirectly cause patients to pay increased costs for their treatments. Patients could experience treatment delays because of supply chain problems. The imposition of potential retaliatory tariffs would result in decreased exports of U.S.-made drugs to foreign markets, which would further burden the sector. The implementation of tariffs would place financial pressure on smaller biotech firms, which currently serve as the main drivers of innovation within the industry. The financial constraints would lead to decreased research in new drugs and result in delayed development of economically feasible treatment methods.

Key Players Landscape and Outlook

Continuous innovation characterizes the landscape of neurodegenerative disease globally, as companies are making substantial investments in research, pursuing strategic partnerships, and accelerating the launch of new products. Gene therapies and RNA-targeting drugs are a primary focus and will be major drivers of growth. The future looks bright, fueled by an aging global population and recent breakthroughs in neuroscience, along with increased investments in precision medicine, AI-assisted drug discovery, and diagnostics.

In January 2025, Eisai Co., Ltd. and Biogen, Inc. jointly announced that they received a grant from the U.S. Food and Drug Administration (FDA) approval for a supplemental Biologics License Application for lecanemab-irmb to maintain the dosing regimen of once every four weeks and offers a potentially more convenient treatment option for eligible patients.

In January 2024, AbbVie Inc. launched PRODUODOPA treatment for advanced Parkinson's, a disease with severe motor-like fluctuations and involuntary movement. It helps patients by extending the period when symptoms are well-controlled by other therapies.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Impact of the U.S. Tariffs

4. Executive Summary

5. Global Neurodegenerative Diseases Market Outlook, 2018-2032F

• 5.1. Market Size Analysis & Forecast
  • 5.1.1. By Value
• 5.2. Market Share Analysis & Forecast
  • 5.2.1. By Indication
    • 5.2.1.1. Alzheimer's Disease
    • 5.2.1.2. Parkinson's Disease
    • 5.2.1.3. Amyotrophic Lateral Sclerosis
    • 5.2.1.4. Huntington's Disease
    • 5.2.1.5. Other Indications
  • 5.2.2. By Drug Class
    • 5.2.2.1. N-methyl-D-aspartate (NMDA) Receptor Antagonists
    • 5.2.2.2. Cholinesterase Inhibitors
    • 5.2.2.3. Dopamine Agonists
    • 5.2.2.4. Immunomodulatory Drugs
    • 5.2.2.5. Other Drug Classes
  • 5.2.3. By Distribution Channel
    • 5.2.3.1. Hospital Pharmacies
    • 5.2.3.2. Retail Pharmacies
    • 5.2.3.3. Online Pharmacies
    • 5.2.3.4. Others
  • 5.2.4. By Region
    • 5.2.4.1. North America
    • 5.2.4.2. Europe
    • 5.2.4.3. Asia-Pacific
    • 5.2.4.4. South America
    • 5.2.4.5. Middle East and Africa
  • 5.2.5. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2024)
• 5.3. Market Map Analysis, 2024
  • 5.3.1. By Indication
  • 5.3.2. By Drug Class
  • 5.3.3. By Distribution Channel
  • 5.3.4. By Region

6. North America Neurodegenerative Diseases Market Outlook, 2018-2032F

• 6.1. Market Size Analysis & Forecast
  • 6.1.1. By Value
• 6.2. Market Share Analysis & Forecast
  • 6.2.1. By Indication
    • 6.2.1.1. Alzheimer's Disease
    • 6.2.1.2. Parkinson's Disease
    • 6.2.1.3. Amyotrophic Lateral Sclerosis
    • 6.2.1.4. Huntington's Disease
    • 6.2.1.5. Other Indications
  • 6.2.2. By Drug Class
    • 6.2.2.1. N-methyl-D-aspartate (NMDA) Receptor Antagonists
    • 6.2.2.2. Cholinesterase Inhibitors
    • 6.2.2.3. Dopamine Agonists
    • 6.2.2.4. Immunomodulatory Drugs
    • 6.2.2.5. Other Drug Classes
  • 6.2.3. By Distribution Channel
    • 6.2.3.1. Hospital Pharmacies
    • 6.2.3.2. Retail Pharmacies
    • 6.2.3.3. Online Pharmacies
    • 6.2.3.4. Others
  • 6.2.4. By Country Share
    • 6.2.4.1. United States
    • 6.2.4.2. Canada
    • 6.2.4.3. Mexico
• 6.3. Country Market Assessment
  • 6.3.1. United States Neurodegenerative Diseases Market Outlook, 2018-2032F*
    • 6.3.1.1. Market Size Analysis & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share Analysis & Forecast
      • 6.3.1.2.1. By Indication
        • 6.3.1.2.1.1. Alzheimer's Disease
        • 6.3.1.2.1.2. Parkinson's Disease
        • 6.3.1.2.1.3. Amyotrophic Lateral Sclerosis
        • 6.3.1.2.1.4. Huntington's Disease
        • 6.3.1.2.1.5. Other Indications
      • 6.3.1.2.2. By Drug Class
        • 6.3.1.2.2.1. N-methyl-D-aspartate (NMDA) Receptor Antagonists
        • 6.3.1.2.2.2. Cholinesterase Inhibitors
        • 6.3.1.2.2.3. Dopamine Agonists
        • 6.3.1.2.2.4. Immunomodulatory Drugs
        • 6.3.1.2.2.5. Other Drug Classes
      • 6.3.1.2.3. By Distribution Channel
        • 6.3.1.2.3.1. Hospital Pharmacies
        • 6.3.1.2.3.2. Retail Pharmacies
        • 6.3.1.2.3.3. Online Pharmacies
        • 6.3.1.2.3.4. Others
  • 6.3.2. Canada
  • 6.3.3. Mexico

All segments will be provided for all regions and countries covered

7. Europe Neurodegenerative Diseases Market Outlook, 2018-2032F

• 7.1. Germany
• 7.2. France
• 7.3. Italy
• 7.4. United Kingdom
• 7.5. Russia
• 7.6. Netherlands
• 7.7. Spain
• 7.8. Turkey
• 7.9. Poland

8. Asia-Pacific Neurodegenerative Diseases Market Outlook, 2018-2032F

• 8.1. India
• 8.2. China
• 8.3. Japan
• 8.4. Australia
• 8.5. Vietnam
• 8.6. South Korea
• 8.7. Indonesia
• 8.8. Philippines

9. South America Neurodegenerative Diseases Market Outlook, 2018-2032F

• 9.1. Brazil
• 9.2. Argentina

10. Middle East and Africa Neurodegenerative Diseases Market Outlook, 2018-2032F

• 10.1. Saudi Arabia
• 10.2. UAE
• 10.3. South Africa

11. Demand Supply Analysis

12. Value Chain Analysis

13. Supply Chain Analysis

14. Porter's Five Forces Analysis

15. PESTLE Analysis

16. Pricing Analysis

17. Market Dynamics

• 17.1. Market Drivers
• 17.2. Market Challenges

18. Market Trends and Developments

19. Regulatory Framework and Innovation

• 19.1. Clinical Trials
• 19.2. Regulatory Approvals

20. Patent Landscape

21. Case Studies

22. Competitive Landscape

• 22.1. Competition Matrix of Top 5 Market Leaders
• 22.2. SWOT Analysis for Top 5 Players
• 22.3. Key Players Landscape for Top 10 Market Players
  • 22.3.1. AbbVie Inc.
    • 22.3.1.1. Company Details
    • 22.3.1.2. Key Management Personnel
    • 22.3.1.3. Products and Services
    • 22.3.1.4. Financials (As Reported)
    • 22.3.1.5. Key Market Focus and Geographical Presence
    • 22.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
  • 22.3.2. Novartis AG
  • 22.3.3. Merck & Co., Inc
  • 22.3.4. Biogen, Inc.
  • 22.3.5. Teva Pharmaceutical Industries Ltd.
  • 22.3.6. Pfizer Inc.
  • 22.3.7. Sanofi S.A
  • 22.3.8. GlaxoSmithKline PLC
  • 22.3.9. UCB S.A.
  • 22.3.10. H. Lundbeck A/S
  • 22.3.11. Boehringer Ingelheim International GmbH

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

23. Strategic Recommendations

24. About Us and Disclaimer

List of Tables

• Table 1. Competition Matrix of Top 5 Market Leaders
• Table 2. Mergers & Acquisitions/ Joint Ventures (If Applicable)
• Table 3. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

• Figure 1. Global Neurodegenerative Disease Market, By Value, In USD Billion, 2018-2032F
• Figure 2. Global Neurodegenerative Disease Market Share (%), By Indication, 2018-2032F
• Figure 3. Global Neurodegenerative Disease Market Share (%), By Drug Class, 2018-2032F
• Figure 4. Global Neurodegenerative Disease Market Share (%), By Distribution Channel, 2018-2032F
• Figure 5. Global Neurodegenerative Disease Market Share (%), By Region, 2018-2032F
• Figure 6. North America Neurodegenerative Disease Market, By Value, In USD Billion, 2018-2032F
• Figure 7. North America Neurodegenerative Disease Market Share (%), By Indication, 2018-2032F
• Figure 8. North America Neurodegenerative Disease Market Share (%), By Drug Class, 2018-2032F
• Figure 9. North America Neurodegenerative Disease Market Share (%), By Distribution Channel, 2018-2032F
• Figure 10. North America Neurodegenerative Disease Market Share (%), By Country, 2018-2032F
• Figure 11. United States Neurodegenerative Disease Market, By Value, In USD Billion, 2018-2032F
• Figure 12. United States Neurodegenerative Disease Market Share (%), By Indication, 2018-2032F
• Figure 13. United States Neurodegenerative Disease Market Share (%), By Drug Class, 2018-2032F
• Figure 14. United States Neurodegenerative Disease Market Share (%), By Distribution Channel, 2018-2032F
• Figure 15. Canada Neurodegenerative Disease Market, By Value, In USD Billion, 2018-2032F
• Figure 16. Canada Neurodegenerative Disease Market Share (%), By Indication, 2018-2032F
• Figure 17. Canada Neurodegenerative Disease Market Share (%), By Drug Class, 2018-2032F
• Figure 18. Canada Neurodegenerative Disease Market Share (%), By Distribution Channel, 2018-2032F
• Figure 19. Mexico Neurodegenerative Disease Market, By Value, In USD Billion, 2018-2032F
• Figure 20. Mexico Neurodegenerative Disease Market Share (%), By Indication, 2018-2032F
• Figure 21. Mexico Neurodegenerative Disease Market Share (%), By Drug Class, 2018-2032F
• Figure 22. Mexico Neurodegenerative Disease Market Share (%), By Distribution Channel, 2018-2032F
• Figure 23. Europe Neurodegenerative Disease Market, By Value, In USD Billion, 2018-2032F
• Figure 24. Europe Neurodegenerative Disease Market Share (%), By Indication, 2018-2032F
• Figure 25. Europe Neurodegenerative Disease Market Share (%), By Drug Class, 2018-2032F
• Figure 26. Europe Neurodegenerative Disease Market Share (%), By Distribution Channel, 2018-2032F
• Figure 27. Europe Neurodegenerative Disease Market Share (%), By Country, 2018-2032F
• Figure 28. Germany Neurodegenerative Disease Market, By Value, In USD Billion, 2018-2032F
• Figure 29. Germany Neurodegenerative Disease Market Share (%), By Indication, 2018-2032F
• Figure 30. Germany Neurodegenerative Disease Market Share (%), By Drug Class, 2018-2032F
• Figure 31. Germany Neurodegenerative Disease Market Share (%), By Distribution Channel, 2018-2032F
• Figure 32. France Neurodegenerative Disease Market, By Value, In USD Billion, 2018-2032F
• Figure 33. France Neurodegenerative Disease Market Share (%), By Indication, 2018-2032F
• Figure 34. France Neurodegenerative Disease Market Share (%), By Drug Class, 2018-2032F
• Figure 35. France Neurodegenerative Disease Market Share (%), By Distribution Channel, 2018-2032F
• Figure 36. Italy Neurodegenerative Disease Market, By Value, In USD Billion, 2018-2032F
• Figure 37. Italy Neurodegenerative Disease Market Share (%), By Indication, 2018-2032F
• Figure 38. Italy Neurodegenerative Disease Market Share (%), By Drug Class, 2018-2032F
• Figure 39. Italy Neurodegenerative Disease Market Share (%), By Distribution Channel, 2018-2032F
• Figure 40. United Kingdom Neurodegenerative Disease Market, By Value, In USD Billion, 2018-2032F
• Figure 41. United Kingdom Neurodegenerative Disease Market Share (%), By Indication, 2018-2032F
• Figure 42. United Kingdom Neurodegenerative Disease Market Share (%), By Drug Class, 2018-2032F
• Figure 43. United Kingdom Neurodegenerative Disease Market Share (%), By Distribution Channel, 2018-2032F
• Figure 44. Russia Neurodegenerative Disease Market, By Value, In USD Billion, 2018-2032F
• Figure 45. Russia Neurodegenerative Disease Market Share (%), By Indication, 2018-2032F
• Figure 46. Russia Neurodegenerative Disease Market Share (%), By Drug Class, 2018-2032F
• Figure 47. Russia Neurodegenerative Disease Market Share (%), By Distribution Channel, 2018-2032F
• Figure 48. Netherlands Neurodegenerative Disease Market, By Value, In USD Billion, 2018-2032F
• Figure 49. Netherlands Neurodegenerative Disease Market Share (%), By Indication, 2018-2032F
• Figure 50. Netherlands Neurodegenerative Disease Market Share (%), By Drug Class, 2018-2032F
• Figure 51. Netherlands Neurodegenerative Disease Market Share (%), By Distribution Channel, 2018-2032F
• Figure 52. Spain Neurodegenerative Disease Market, By Value, In USD Billion, 2018-2032F
• Figure 53. Spain Neurodegenerative Disease Market Share (%), By Indication, 2018-2032F
• Figure 54. Spain Neurodegenerative Disease Market Share (%), By Drug Class, 2018-2032F
• Figure 55. Spain Neurodegenerative Disease Market Share (%), By Distribution Channel, 2018-2032F
• Figure 56. Turkey Neurodegenerative Disease Market, By Value, In USD Billion, 2018-2032F
• Figure 57. Turkey Neurodegenerative Disease Market Share (%), By Indication, 2018-2032F
• Figure 58. Turkey Neurodegenerative Disease Market Share (%), By Drug Class, 2018-2032F
• Figure 59. Turkey Neurodegenerative Disease Market Share (%), By Distribution Channel, 2018-2032F
• Figure 60. Poland Neurodegenerative Disease Market, By Value, In USD Billion, 2018-2032F
• Figure 61. Poland Neurodegenerative Disease Market Share (%), By Indication, 2018-2032F
• Figure 62. Poland Neurodegenerative Disease Market Share (%), By Drug Class, 2018-2032F
• Figure 63. Poland Neurodegenerative Disease Market Share (%), By Distribution Channel, 2018-2032F
• Figure 64. South America Neurodegenerative Disease Market, By Value, In USD Billion, 2018-2032F
• Figure 65. South America Neurodegenerative Disease Market Share (%), By Indication, 2018-2032F
• Figure 66. South America Neurodegenerative Disease Market Share (%), By Drug Class, 2018-2032F
• Figure 67. South America Neurodegenerative Disease Market Share (%), By Distribution Channel, 2018-2032F
• Figure 68. South America Neurodegenerative Disease Market Share (%), By Country, 2018-2032F
• Figure 69. Brazil Neurodegenerative Disease Market, By Value, In USD Billion, 2018-2032F
• Figure 70. Brazil Neurodegenerative Disease Market Share (%), By Indication, 2018-2032F
• Figure 71. Brazil Neurodegenerative Disease Market Share (%), By Drug Class, 2018-2032F
• Figure 72. Brazil Neurodegenerative Disease Market Share (%), By Distribution Channel, 2018-2032F
• Figure 73. Argentina Neurodegenerative Disease Market, By Value, In USD Billion, 2018-2032F
• Figure 74. Argentina Neurodegenerative Disease Market Share (%), By Indication, 2018-2032F
• Figure 75. Argentina Neurodegenerative Disease Market Share (%), By Drug Class, 2018-2032F
• Figure 76. Argentina Neurodegenerative Disease Market Share (%), By Distribution Channel, 2018-2032F
• Figure 77. Asia-Pacific Neurodegenerative Disease Market, By Value, In USD Billion, 2018-2032F
• Figure 78. Asia-Pacific Neurodegenerative Disease Market Share (%), By Indication, 2018-2032F
• Figure 79. Asia-Pacific Neurodegenerative Disease Market Share (%), By Drug Class, 2018-2032F
• Figure 80. Asia-Pacific Neurodegenerative Disease Market Share (%), By Distribution Channel, 2018-2032F
• Figure 81. Asia-Pacific Neurodegenerative Disease Market Share (%), By Country, 2018-2032F
• Figure 82. India Neurodegenerative Disease Market, By Value, In USD Billion, 2018-2032F
• Figure 83. India Neurodegenerative Disease Market Share (%), By Indication, 2018-2032F
• Figure 84. India Neurodegenerative Disease Market Share (%), By Drug Class, 2018-2032F
• Figure 85. India Neurodegenerative Disease Market Share (%), By Distribution Channel, 2018-2032F
• Figure 86. China Neurodegenerative Disease Market, By Value, In USD Billion, 2018-2032F
• Figure 87. China Neurodegenerative Disease Market Share (%), By Indication, 2018-2032F
• Figure 88. China Neurodegenerative Disease Market Share (%), By Drug Class, 2018-2032F
• Figure 89. China Neurodegenerative Disease Market Share (%), By Distribution Channel, 2018-2032F
• Figure 90. Japan Neurodegenerative Disease Market, By Value, In USD Billion, 2018-2032F
• Figure 91. Japan Neurodegenerative Disease Market Share (%), By Indication, 2018-2032F
• Figure 92. Japan Neurodegenerative Disease Market Share (%), By Drug Class, 2018-2032F
• Figure 93. Japan Neurodegenerative Disease Market Share (%), By Distribution Channel, 2018-2032F
• Figure 94. Australia Neurodegenerative Disease Market, By Value, In USD Billion, 2018-2032F
• Figure 95. Australia Neurodegenerative Disease Market Share (%), By Indication, 2018-2032F
• Figure 96. Australia Neurodegenerative Disease Market Share (%), By Drug Class, 2018-2032F
• Figure 97. Australia Neurodegenerative Disease Market Share (%), By Distribution Channel, 2018-2032F
• Figure 98. Vietnam Neurodegenerative Disease Market, By Value, In USD Billion, 2018-2032F
• Figure 99. Vietnam Neurodegenerative Disease Market Share (%), By Indication, 2018-2032F
• Figure 100. Vietnam Neurodegenerative Disease Market Share (%), By Drug Class, 2018-2032F
• Figure 101. Vietnam Neurodegenerative Disease Market Share (%), By Distribution Channel, 2018-2032F
• Figure 102. South Korea Neurodegenerative Disease Market, By Value, In USD Billion, 2018-2032F
• Figure 103. South Korea Neurodegenerative Disease Market Share (%), By Indication, 2018-2032F
• Figure 104. South Korea Neurodegenerative Disease Market Share (%), By Drug Class, 2018-2032F
• Figure 105. South Korea Neurodegenerative Disease Market Share (%), By Distribution Channel, 2018-2032F
• Figure 106. Indonesia Neurodegenerative Disease Market, By Value, In USD Billion, 2018-2032F
• Figure 107. Indonesia Neurodegenerative Disease Market Share (%), By Indication, 2018-2032F
• Figure 108. Indonesia Neurodegenerative Disease Market Share (%), By Drug Class, 2018-2032F
• Figure 109. Indonesia Neurodegenerative Disease Market Share (%), By Distribution Channel, 2018-2032F
• Figure 110. Philippines Neurodegenerative Disease Market, By Value, In USD Billion, 2018-2032F
• Figure 111. Philippines Neurodegenerative Disease Market Share (%), By Indication, 2018-2032F
• Figure 112. Philippines Neurodegenerative Disease Market Share (%), By Drug Class, 2018-2032F
• Figure 113. Philippines Neurodegenerative Disease Market Share (%), By Distribution Channel, 2018-2032F
• Figure 114. Middle East & Africa Neurodegenerative Disease Market, By Value, In USD Billion, 2018-2032F
• Figure 115. Middle East & Africa Neurodegenerative Disease Market Share (%), By Indication, 2018-2032F
• Figure 116. Middle East & Africa Neurodegenerative Disease Market Share (%), By Drug Class, 2018-2032F
• Figure 117. Middle East & Africa Neurodegenerative Disease Market Share (%), By Distribution Channel, 2018-2032F
• Figure 118. Middle East & Africa Neurodegenerative Disease Market Share (%), By Country, 2018-2032F
• Figure 119. Saudi Arabia Neurodegenerative Disease Market, By Value, In USD Billion, 2018-2032F
• Figure 120. Saudi Arabia Neurodegenerative Disease Market Share (%), By Indication, 2018-2032F
• Figure 121. Saudi Arabia Neurodegenerative Disease Market Share (%), By Drug Class, 2018-2032F
• Figure 122. Saudi Arabia Neurodegenerative Disease Market Share (%), By Distribution Channel, 2018-2032F
• Figure 123. UAE Neurodegenerative Disease Market, By Value, In USD Billion, 2018-2032F
• Figure 124. UAE Neurodegenerative Disease Market Share (%), By Indication, 2018-2032F
• Figure 125. UAE Neurodegenerative Disease Market Share (%), By Drug Class, 2018-2032F
• Figure 126. UAE Neurodegenerative Disease Market Share (%), By Distribution Channel, 2018-2032F
• Figure 127. South Africa Neurodegenerative Disease Market, By Value, In USD Billion, 2018-2032F
• Figure 128. South Africa Neurodegenerative Disease Market Share (%), By Indication, 2018-2032F
• Figure 129. South Africa Neurodegenerative Disease Market Share (%), By Drug Class, 2018-2032F
• Figure 130. South Africa Neurodegenerative Disease Market Share (%), By Distribution Channel, 2018-2032F
• Figure 131. By Indication Map-Market Size (USD Billion) & Growth Rate (%), 2024
• Figure 132. By Drug Class Map-Market Size (USD Billion) & Growth Rate (%), 2024
• Figure 133. By Distribution Channel Map-Market Size (USD Billion) & Growth Rate (%), 2024
• Figure 134. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2024